We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




POC Glucose Monitoring Devices Market to Reach USD 2 Billion in 2022

By LabMedica International staff writers
Posted on 04 Apr 2018
The global POC blood glucose monitoring devices market is expected to reach USD 2.03 billion in 2022, driven mainly by public and private initiatives to reduce diabetic cases. More...
However, the high cost associated with diabetes management is one of the major factors hindering the market growth.

These are the latest findings of Research and Markets, (Dublin, Ireland), a global market research company.

Most POC blood glucose monitoring devices manufactured by global and local players are cost-efficient. However, the cost associated with diabetes management in high, resulting in out-of-pocket expenditure for consumables used in POC blood glucose monitoring devices. These consumables, including blood glucose test strips, reagents, and cassettes are expensive and are required on a daily basis. Moreover, an invasive device such as lancet needs to be purchased separately along with the POC blood monitoring devices, resulting in additional cost being incurred.

Of late, there has been a paradigm shift to non-invasive products in the POC blood glucose monitoring devices market. Non-invasive POC blood glucose monitoring devices are hand-held units that offer a number of benefits over finger prick glucose test, such as helping to avoid finger prick and providing a convenient, easy to read large number display. Non-invasive POC blood glucose monitoring devices can also track patient compliance and allow multiple tests to be run in order to allow healthcare providers to provide adequate therapeutic decisions.

Related Links:
Research and Markets


New
Gold Member
Latex Test
SLE-Latex Test
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Silver Member
Quality Control Material
Multichem ID-B
New
Drug Test Kit
DrugCheck 3000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.